Want to see SNDX full AI Analyst Report?
SNDX Stock Chart & Stats
$24.23
$0.12(0.87%)
At close: 4:00 PM EST
$24.23
$0.12(0.87%)
Day’s Range― - ―
52-Week Range$8.59 - $25.59
Previous CloseN/A
Volume201.89K
Average Volume (3M)1.81M
Market Cap
$1.93B
Enterprise Value$1.90B
Total Cash (Recent Filing)$352.06M
Total Debt (Recent Filing)$345.36M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 10, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.80
Shares Outstanding88,610,020
10 Day Avg. Volume2,051,473
30 Day Avg. Volume1,808,668
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)28.16
Price to Sales (P/S)10.56
P/FCF Ratio-5.63
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue8.76
Enterprise Value/Gross Profit8.94
Enterprise Value/Ebitda-11.70
Forecast
1Y Price Target
$36.38Price Target Upside50.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.79
Revenue Forecast (FY)$346.20M
Bulls Say, Bears Say
Bulls Say
Revenue & Gross MarginSyndax’s durable top-line growth (+26% TTM) combined with an exceptionally high gross margin (~96%) indicates strong pricing power and scalable product economics in oncology. This supports long-term reinvestment in R&D and commercialization, improving odds of moving toward sustainable cash generation if growth persists.
Improved LeverageLeverage falling to zero materially lowers financial risk and interest obligations, giving management more flexibility to allocate cash toward operations or development. With limited debt, the company can better manage runway and financing choices over the coming months while focusing on commercialization execution.
Material Capital RaiseThe $250M convertible note financing provides multi-quarter runway and funds commercialization, R&D, and business development. Securing low-coupon, convertible capital reduces immediate liquidity pressure and supports execution of strategic plans without near-term cash-flow stress, enabling focus on durable growth drivers.
Bears Say
High Cash BurnSustained operating and free cash flow deficits (~-$278M TTM) create ongoing funding needs that materially raise dilution and refinancing risk. Unless revenue scales rapidly or spending is curtailed, persistent cash burn will constrain strategic choices and can force financing at unfavorable terms within months.
Large Net LossesThe company remains deeply unprofitable (net loss ~ $243M, -112% margin), reflecting heavy operating spend versus current revenue base. Persistent large losses erode capital and require continual external funding, increasing execution risk and pressuring management to achieve durable margin expansion or faster revenue scale.
Thin Equity CushionA small equity base (~$42M) provides limited buffer against further losses and heightens insolvency risk if operating performance deteriorates. This thin cushion increases the probability of dilutive equity raises or onerous financing terms over the medium term, constraining strategic optionality.
Syndax Pharmaceuticals News
SNDX FAQ
What was Syndax Pharmaceuticals Inc.’s price range in the past 12 months?
Syndax Pharmaceuticals Inc. lowest stock price was $8.59 and its highest was $25.59 in the past 12 months.
What is Syndax Pharmaceuticals Inc.’s market cap?
Syndax Pharmaceuticals Inc.’s market cap is $1.93B.
When is Syndax Pharmaceuticals Inc.’s upcoming earnings report date?
Syndax Pharmaceuticals Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 36 days.
How were Syndax Pharmaceuticals Inc.’s earnings last quarter?
Syndax Pharmaceuticals Inc. released its earnings results on Apr 30, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.608 by $0.128.
Is Syndax Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc.’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc. pay dividends?
Syndax Pharmaceuticals Inc. does not currently pay dividends.
What is Syndax Pharmaceuticals Inc.’s EPS estimate?
Syndax Pharmaceuticals Inc.’s EPS estimate is -0.48.
How many shares outstanding does Syndax Pharmaceuticals Inc. have?
Syndax Pharmaceuticals Inc. has 88,610,020 shares outstanding.
What happened to Syndax Pharmaceuticals Inc.’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.608. Following the earnings report the stock price went down -10.826%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in SNDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syndax Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.38 (50.12% Upside)
$36.38 (50.12% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
142.44%
12-Months-Change
Fundamentals
Return on Equity
-256.66%
Trailing 12-Months
Asset Growth
-26.23%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
SNDX Company Deck
SNDX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful scientific progress: two successful launches, accelerating quarter-over-quarter revenue growth (Revuforj +38% QoQ; Niktimvo +22% QoQ), solid real-world evidence, a healthy year-end cash balance ($394M) and multiple near- and mid-term clinical catalysts (frontline pivotal trials and an IPF readout). Offsetting factors include a high 2026 expense run-rate (~$400M), still-short average treatment duration in year one for Revuforj (4–6 months), incomplete post-transplant maintenance uptake (~40%–45%) and the risk that pending clinical readouts or competitive dynamics could temper expectations. On balance, highlights and growth drivers substantially outweigh near-term risks, but upcoming readouts and execution on duration/maintenance adoption and expense control are critical.View all SNDX earnings summariesSNDX Stock 12 Month Forecast
Average Price Target
$36.38
▲(50.12% Upside)
Technical Analysis
Ownership Overview
1.61% Insiders
15.46% Mutual Funds
48.92% Other Institutional Investors
17.74% Public Companies and
Individual Investors